PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of nihpaAbout Author manuscriptsSubmit a manuscriptHHS Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
 
J Immunol. Author manuscript; available in PMC 2013 August 1.
Published in final edited form as:
PMCID: PMC3401274
NIHMSID: NIHMS381077

Diet-induced obesity alters dendritic cell function in the presence and absence of tumor growth

Abstract

Obesity is a mounting health concern in the United States, and is associated with an increased risk for developing several cancers, including renal cell carcinoma (RCC). Despite this, little is known regarding the impact of obesity on antitumor immunity. As dendritic cells (DC) are critical regulators of antitumor immunity, we examined the combined effects of obesity and tumor outgrowth on DC function. Using a diet-induced obesity (DIO) model, DC function was evaluated in mice bearing orthotopic RCC and in tumor-free controls. Tumor-free DIO mice had profoundly altered serum cytokine and chemokine profiles, with upregulation of 15 proteins, including IL-1α, IL-17, and LIF. Tumor-free DIO mice had elevated percentages of conventional splenic DC that were impaired in their ability to stimulate naive T cell expansion, although they were phenotypically similar to normal weight (NW) controls. In DIO mice, intra-renal RCC tumor challenge in the absence of therapy led to increased local infiltration by T cell-suppressive DC and accelerated early tumor outgrowth. Following administration of a DC-dependent immunotherapy, established RCC tumors regressed in NW mice. The same immunotherapy was ineffective in DIO mice, and was characterized by an accumulation of regulatory DC in tumor-bearing kidneys, decreased local infiltration by IFNγ-producing CD8 T cells, and progressive tumor outgrowth. Our results suggest that the presence of obesity as a co-morbidity can impair the efficacy of DC-dependent antitumor immunotherapies.

Introduction

In the U.S. today, over 50% of adults are overweight or obese. These conditions are associated with a variety of health problems, including an increased risk for developing post-menopausal breast cancer, esophageal cancer, and renal cell carcinoma (RCC) (13). The reasons for this are unclear, but may include such factors as increased rates of tumorigenesis, accelerated tumor outgrowth, and diminished antitumor immunity. Currently, the confounding effects of obesity on immunotherapeutic efficacy in cancer patients are unknown, and given the number of adults affected by obesity, more research in this area is needed.

Obesity is characterized by numerous physiological changes that may directly or indirectly influence the immune system. In the obese, visceral adipocytes secrete high levels of pro-inflammatory cytokines such as leptin, TNFα, and IL-6, triggering a chronic, low-grade systemic inflammation (48). In mice, obesity can be induced through either genetic means or prolonged feeding of high fat feed (HFF). Although genetic leptin deficiency leads to the rapid onset of obesity, diet-induced obesity (DIO) represents a clinically relevant model with slower progression, increased leptin production, and systemic inflammation (911).

Studies on tumor-free DIO mice have illustrated a number of alterations in leukocyte function. For example, DIO has been linked to mesenteric lymph node atrophy, altered differentiation of adipose tissue macrophages, decreased stimulatory capacity in bulk splenic APCs, diminished DC antigen presentation during influenza infection, reduced secondary expansion of CD8+ T cells, and reduced IFNγ production by memory T cells (1217). In addition, leptin-deficient ob/ob mice were found to have increased percentages of CD11c+ splenocytes that had reduced stimulatory capacity (12). At this time, a thorough evaluation of highly purified, steady-state DC from DIO mice has not been performed, and the DC response to combined obesity and tumor outgrowth is unclear. The aforementioned findings suggest that DC-dependent, antitumor immunotherapies would be less effective in the obese, but this has not yet been demonstrated.

DC are key regulators of T cell immunity, therefore normal DC function is essential for achieving T cell-mediated tumor clearance. Given the importance of understanding how obesity and tumor outgrowth collectively impact immune function, we examined how obesity influences DC function in the presence and absence of tumor growth. For tumor studies, we used an orthotopic RCC model, in which parental or luciferase-expressing Renca tumor cells were injected directly into murine kidneys, then measured renal tumor growth via flow cytometry or bioluminescent imaging (BLI) of live mice. We then administered a DC-dependent immunotherapy, and found that its efficacy was greatly reduced in DIO mice. Our findings suggest that pre-clinical murine studies evaluating the efficacy of novel immunotherapies should examine host responsiveness in not only normal weight (NW) mice, but also in obese mice, as results in the latter may differ substantially. Doing so may speed the development of immunotherapeutic regimens that show efficacy in obese cancer patients.

Materials and Methods

Animals and Diets

Female BALB/c mice were purchased (Harlan Laboratories) at 7–8 weeks of age, maintained on standard chow for one week after receipt, then randomly assigned to either standard chow or high fat feed (HFF) (Research Diets # 12492, 60% kcal from fat) for 20 weeks. Mice were housed 5 to a cage under pathogen-free conditions at the University of Iowa Animal Care Facility, which is fully accredited by the Association for Accreditation of Laboratory Animal Care. All animal procedures were approved by the University of Iowa Institutional Animal Care and Use Committee. After 20 weeks on feed, all mice were weighed, and the mean and s.d. of the NW (standard chow) group were calculated. Mice in the HFF group were defined as being diet-induced obese (DIO) if their body weight at this time point was greater than 3 s.d. above the mean of the NW group.

Tumor cell line and tumor challenge

The murine renal adenocarcinoma cell line Renca was obtained from Dr. Robert Wiltrout (National Cancer Institute, Frederick, MD), and was authenticated in 2010 by microsatellite marker analysis (Research Animal Diagnostic Laboratory, Columbia, MO). Renca cells were maintained in Complete RPMI as previously described (18). Renca-Luc is a variant that stably expresses firefly Luciferase; it was generated via retroviral transduction as described (19, 20). Renca-Luc cells were maintained in Complete RPMI supplemented with 0.05µg/ml puromycin.

For intra-renal (IR) tumor challenge, a skin incision was made on the left flank, and 2 × 105 Renca-Luc cells were injected through the intact peritoneum into the left kidney. On d 7 following tumor challenge, mice were re-injected in the same kidney with either sterile PBS or 109 pfu of Ad5mTRAIL (18) plus 100 µg CpG1826 (Coley Pharmaceuticals, Wellesley, MA), in a 100 µl volume. Renal tumor growth in vivo was measured via BLI (University of Iowa Central Microscopy Core Facility). For experiments on DC function in tumor-bearing mice, renal tumor growth was validated by Bioluminescent Imaging (BLI) prior to sacrifice, typically between days 21–28. For sc tumor growth, 2 × 105 parental Renca tumor cells were injected on d0, followed by sterile PBS or Ad5mTRAIL+CpG1826, as above, given peri-tumorally on d7.

Bioluminescent Imaging (BLI) of tumor growth

BLI was done using an IVIS 200 (Caliper Life Sciences, Hopkinton, MA) as described (19, 20). Briefly, 10 min prior to imaging, mice were injected i.p. with 100 µl of a 15 mg/ml solution of D-Luciferin (GoldBio.com; St. Louis, MO), then anesthetized via inhalation of oxygenated isoflurane. Live mice were imaged for 1 min each for dorsal and ventral aspects. Renca-Luc generated photon flux (photons/second) was calculated within a defined region of interest using Living Image software (Version 2.5, Caliper Life Sciences). The mean total flux per mouse (average of dorsal and ventral images) was determined at the indicated time points, and used to calculate an overall mean for each treatment group.

DC and T cell enrichment and isolation

DC were harvested from spleens or tumor-bearing kidneys, as indicated. Organs were removed, manually disrupted, then digested for 15–30 minutes in HBSS containing 0.56 Wuensch units/ml of Liberase Blendzyme 3 (Roche, Branford, CT) and 0.15mg/ml DNAse I (Sigma Chemical, St. Louis, MO). Single cell suspensions were prepared as described (21). DC were enriched using Miltenyi anti-CD11c microbeads (21) then sort-purified on a BD Aria II or Facs DiVa based on expression of the following markers: CD45+/ CD11chigh/ CD11b+/ Gr-1 after gating on live cells via Hoechst 33258 exclusion.

T cell proliferation and inhibition assays

T cells were harvested from DUC18 TCR transgenic mice (22, 23), incubated with CD8α microbeads (Miltenyi) and purified over two sequential MACS columns. The percentage of DUC18 T cells was determined via flow cytometry, based on surface co-expression of CD8α and Vβ8.3. T cells were used in proliferation assays with sort-purified splenic DC (spDC) from either NW or DIO tumor-free mice, which were set up as described (21). DC inhibition of T cell proliferation was assessed by culturing naive DUC18 T cells (5 × 104 cells per well) with tERK peptide-pulsed spDC (2123) from control, tumor-free BALB/c mice (5× 103 cells per well) and sort-purified renal DC from tumor-bearing mice (5× 103 cells per well). 3HThymidine was added on d3 for the final 18 hr of culture. T cell inhibition was calculated as the % decrease in T cell proliferation with renal DC present relative to that seen for DUC18 T cells cultured with control, peptide-pulsed spDC alone (21).

Surface staining for flow cytometry

Spleens and tumor-free or tumor-bearing kidneys were harvested, manually disrupted, then digested as above. Cells were stained with combinations of the following mAb, and results acquired using multi-parameter flow cytometry on a BD LSR II (BD Biosciences, San Diego, CA) then analyzed with FlowJo software (TreeStar Inc., Ashland, OR). For DC: CD11c-biotin, streptavidin-APC/Cy7, CD11b-PE/Cy7, Gr1-APC, I-Ad-PE, CD4-FITC, CD8- PerCP-Cy5.5, CD83-A488, CD86-APC, H-2Kd−FITC, CD40-APC and Hoechst; for T cells: CD3-PE, CD8-APC, CD4-PE/Cy7, CD11a-FITC, IFNγ-PerCP-Cy5.5, and Hoechst; for Renca tumor cells: Rae1γ-A647 and purified anti-CAR + goat anti-mouse A488. mAb were from eBioscience (San Diego, CA), BioLegend (San Diego, CA), or Millipore (Billerica, MA).

Cytokine and Chemokine evaluation by ELISA and BioPlex

Serum samples were obtained from NW or DIO mice and frozen at −80C until use. DC were purified from spleens or tumor-bearing kidneys and cultured ON at 5 × 105 cells/ml in complete medium in the presence or absence of 1µg/ml LPS (Sigma). Supernatants were harvested and frozen at −80C until use. Leptin serum concentrations were determined by ELISA (ChrystalChem) according to the manufacturer’s protocol. Serum and supernatant concentrations of the following cytokines and chemokines were determined via Multiplex analysis (Milliplex MAP kits, Millipore) on a BioRad BioPlex: Eotaxin, G-CSF, IFNγ, IP-10, KC, LIF, LIX, MIP-2, TNFα, VEGF, MDC, IL-1α, IL-1β, Il-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-10, IL-12p40, IL-12p70, Il-13, IL-15, IL-17, IL-23, IL-27.

Statistical Analyses

Statistical significance between experimental groups was determined by using paired or unpaired Student’s t-tests, with Welch’s corrections for unequal variances, as appropriate (Prism, GrpahPad Software Inc., La Jolla, CA). Throughout the manuscript, significance at p< .05 is indicated by one asterisk, p< .01 is indicated by two asterisks.

Results

Profoundly altered serum cytokine profile in female BALB/c DIO mice

The majority of prior studies on murine DIO used the C57Bl/6 strain, as these mice rapidly become obese after being placed on HFF (911, 13, 17, 24). As our goal was to determine the combined effects of renal tumor outgrowth and DIO on DC function, our experimental model necessitated using the BALB/c strain for Renca RCC tumor challenge. We found that BALB/c mice are more resistant to DIO than are C57Bl/6 mice, and BALB/c mice placed on HFF for 10 weeks did not develop the systemic inflammation that normally accompanies DIO (data not shown). Consequently, we modified our protocol so that BALB/c mice were fed HFF for 20 weeks, and performed a thorough characterization of the resulting DIO mice.

We observed that 45– 55% of BALB/c mice on HFF showed increased weight gain relative to age-matched mice fed standard chow over the same period of time (Fig. 1A). Therefore, we defined DIO mice as those having a final weight of greater than the mean weight plus 3 s.d. of age-matched NW mice that had been fed standard chow for 20 weeks. The mean body weights of one cohort of 13 NW and 13 DIO mice are shown in Fig. 1B. Compared to NW mice, DIO mice had increased percentages of visceral body fat and increased concentrations of serum leptin (Fig. 1C and D), both of which are hallmarks of obesity.

FIGURE 1
BALB/c DIO mice show characteristic hallmarks of obesity. A, Final body weights for individual mice are shown after being on either standard chow (normal weight “NW”) or HFF for 20 weeks. The dashed line indicates 3 s.d. above the NW mean. ...

We next tested serum from NW and DIO mice for concentrations of 35 individual cytokines and chemokines via multiplex array. Of these, only IL-5 and VEGF were elevated in NW vs DIO serum (Table 1). In contrast, a large number of analytes showed statistically significant increases in DIO versus NW serum, including IL-1α, IL-7, IL-15, IL-17, IFNγ, IP-10, LIF, LIX, and TNFα. These data illustrate that placing BALB/c mice on HFF for 20 weeks generates a robust obesity characterized by systemic inflammation.

Table I
Serum cytokine and chemokine profiles for NW versus DIO mice. Serum was harvested from NW or DIO mice (n= 6 NW, n= 7 DIO) after 20 wks on feed, frozen, and analyzed via MultiPlex array for the above analytes.

Increased percentages of conventional splenic DC in DIO mice

As a prior report had shown increased percentages of CD11c+/ MHC II+ splenic DC (spDC) in leptin-deficient ob/ob C57Bl/6 mice (12), we examined the percentages of steady-state spDC in BALB/c DIO mice to determine if these mice also had increased percentages of spDC. Conventional spDC are identified by high CD11c expression, which differentiates them from other cell populations that can express intermediate to low levels of this integrin (25, 26). Figure 2A shows the gating strategy used to identify spDC. We observed increased percentages of CD11chigh spDC in DIO mice (Fig. 2B). An analysis of CD11chigh DC subsets revealed equivalent percentages of CD8α+ DC, CD4+DC, CD11b+ DC, and CD8/ CD4 double negative DC in the spleens of NW and DIO mice (Supplemental Figure 1A). In addition, we also detected higher percentages of CD11clow/ MHC II+/B220+ plasmacytoid DC in the spleens of DIO mice (Supplemental Figure 1B). Of note, total live splenocyte counts were nearly identical in NW and DIO mice (Fig. 2C), indicating that the obesity- associated inflammation had not resulted in overall increases in splenic cellularity. Thus, our findings in BALB/c DIO mice support those reported earlier by Macia et al. during their study of leptin-deficient obese mice (12).

FIGURE 2
Increased percentages of conventional spDC in DIO mice. A, Flow cytometric analysis of spDC populations from NW and DIO mice. Dot plots from individual mice are shown, representative of data from 13 NW and 13 DIO mice. B, Mean +/− SEM percentages ...

Lymph node (LN) DC subset composition has not been thoroughly examined in DIO mice. We isolated brachial, axillary, and inguinal LNs from DIO and NW mice, and determined the frequencies of total DC in pooled LNs, as well as percentages of the three main DC subpopulations present, based on expression of CD11c and MHC II (I-Ad). Tissue-derived migratory DC are defined as CD11c+/ MHC IIhigh (subset i), inflammatory DC as CD11c+/ MHC II+ (subset ii), and LN-resident DC as CD11chigh/ MHC II+ (subset iii) (Supplemental Fig. 1C)(27). DIO mice had increased percentages of total LN DC as compared to NW mice (Supplemental Fig. 1C). No statistically significant alterations were observed in the percentages of any of the LN subsets in DIO versus NW mice, although there was a trend in each case toward increased percentages with obesity (Supplemental Fig. 1D). Together, these results show that DC subset composition is similar between NW and DIO mice, but that greater percentages of conventional spDC, plasmacytoid spDC, and LN DC are present in DIO mice.

Decreased stimulatory capacity but increased CXCL10 production in DIO spDC

Previous investigations into the effects of obesity on DC stimulatory capacity produced conflicting results. Studies on naive animals had found that bulk splenic APCs from DIO mice and bone-marrow-derived DC from leptin-deficient ob/ob mice were less able to stimulate naive T cell proliferation than were cellular counterparts from NW mice (12, 14). In contrast, another report found that during influenza infection, lung DC from DIO mice retained the ability to induce IFNγ production in T cells (17). Therefore, our next set of experiments addressed whether DIO impacted the steady-state stimulatory capacity of highly purified spDC.

For these experiments, spDC were sort-purified from NW or DIO mice by gating on CD45+/ Gr-1neg/ CD11chigh/ CD11b+ cells. We focused on CD11b+ DC, as we had determined previously that this subpopulation accumulated within murine fibrosarcomas and mammary carcinomas (21); we therefore wanted to determine if baseline differences were present in the stimulatory capacity of this DC subset in tumor-free DIO versus NW mice. Following purification, spDC were pulsed with tERK peptide and used to stimulate CD8+ TCR-transgenic DUC18 T cells in vitro (2123, 28). The results of 4 independent experiments illustrate that spDC from DIO mice induced less T cell proliferation than their NW counterparts (Fig. 3A and B). Overall, mean T cell proliferation in the presence of DIO spDC was 58% of that seen with NW spDC.

FIGURE 3
Decreased stimulatory capacity but increased IP-10 production in DIO spDC. A, Individual results from 1 independent T cell proliferation assay using sort-purified, tERK-pulsed spDC and enriched CD8+ DUC18 T cells. The mean +/− SEM for triplicate ...

To determine if obvious phenotypic differences might account for the decreased stimulatory capacity observed in DIO spDC, bulk splenocytes from NW and DIO mice were stained as indicated (Fig. 3C). Gating on the CD11chigh/CD11b+/I-Ad+ spDC population revealed no significant alterations in surface expression of MHC I, MHC II, CD86, or CD40 between NW and DIO mice.

We then asked if DIO spDC possessed an altered cytokine/ chemokine profile as compared to NW spDC, since DC-derived cytokines can profoundly alter T cell differentiation outcomes (29). Following an overnight DC culture with LPS, supernatants were harvested from either DIO or NW spDC cultures, and analyzed via multiplex array for a panel of 24 cytokines and chemokines. The only significant difference found was in the production of the chemokine IP-10, which was higher in DIO spDC than NW spDC (Fig. 3D and Supplemental Table I). For many analytes, such as IL-6, the expression patterns were nearly identical between the two groups, whereas for others, such as MIP-2, trends were visible but did not reach statistical significance. Overall, the phenotypes and chemokine/ cytokine profiles in DIO and NW spDC were largely comparable; thus major difference we detected was a defect in DIO spDC stimulatory capacity.

Increased numbers of inhibitory DC infiltrate renal tumors from DIO mice

Once a baseline examination of steady-state spDC function had been performed in tumor-free DIO versus NW mice, we examined the combined effects of tumor outgrowth and obesity on DC function. We had found previously that tumor-infiltrating CD11c+/CD11b+/Gr-1neg DC (TIDC) from NW mice acted as regulatory cells that suppressed T cell proliferation ex vivo and impeded antitumor immunity in vivo, leading to enhanced tumor outgrowth (21). Currently, the impact of obesity on antitumor immunity is unclear, and it is not known how or whether obesity and tumor growth interact to further alter DC function.

Our experiments made use of an orthotopic RCC model, in which luciferase-expressing Renca tumor cells were injected directly into the left kidney of DIO or NW mice after 20 weeks of feeding either HFF (DIO) or standard chow (NW). This system allowed us to measure renal tumor burdens over time in live mice via BLI. BLI revealed that early tumor growth through d7 was more rapid in DIO mice as compared to NW counterparts (Fig. 4A and Supplemental Fig. 2A). Despite this fact, kidney masses remained comparable at d7 (Fig. 4B), as renal tumors are not yet macroscopically visible at this time point in our model system (30). Therefore, to validate our BLI observation at d7, we performed a complementary analysis by performing flow cytometry on dissociated kidneys from NW and DIO mice. Mice were challenged IR with parental Renca, then both tumor-bearing and contralateral kidneys were isolated from each animal and stained for Rae1γ, an NKG2D ligand known to be expressed on Renca cells (31). Although Rae1γ is expressed on cell types other than Renca tumors, the low baseline staining in tumor-free contralateral kidneys (30) from both NW and DIO mice shows that Rae1γ can be used to assess Renca tumor burdens in murine kidneys (Fig. 4C). This staining approach validated our BLI results, by showing increased tumor burdens in DIO kidneys at d7 relative to NW kidneys, and also illustrated that early increases in DIO tumor burdens are not sustained over time.

FIGURE 4
Accelerated early renal tumor growth in DIO mice. A, Mice were challenged IR with Renca-Luc cells on d0. At d7, relative tumor burdens were evaluated via BLI of live mice after ip injection of luciferin substrate. Total flux indicates light emitted by ...

To determine if obesity fundamentally altered the DC response to progressing solid tumor development, we examined DC infiltration into tumor-bearing kidneys over time in NW and DIO mice. First, however, we examined the percentages of CD11chigh/ MHC II+ renal DC (Supplemental Fig. 2B), and the total numbers of live cells per kidney (data not shown) in tumor-free NW and DIO mice, and found them to be equivalent. An examination of Renca tumor-bearing kidneys illustrated that DIO and NW mice had comparable percentages of DC at both d7 and d13 after tumor-challenge (Fig. 5A). The percentages of DC in Renca-positive kidneys were increased at d7, relative to tumor-free contralateral kidneys, in both DIO and NW mice. As an additional control, we injected some mice IR with sterile PBS, to evaluate whether local inflammation caused by the IR injection itself led to local DC infiltration, or whether the responses observed were specific to tumor growth. The percentages of DC in PBS-injected kidneys were comparable to those seen in tumor-free contralateral kidneys, indicating that heightened DC infiltration in tumor-bearing kidneys was a response to local tumor growth. Phenotypic analysis of renal DC at d7 illustrated that DIO mice had fewer CD83+ DC, suggesting that DC were less mature (32). Expression of CD86 was similar on NW and DIO renal DC at both d7 and d13, and was elevated on DC from tumor-bearing kidneys relative to contralateral or PBS-injected kidneys (Supplemental Fig. 2C).

FIGURE 5
Increased local infiltration of suppressive DC into tumor-bearing kidneys in DIO mice. A, The mean +/− SEM percentage of renal DC in tumor-bearing (tum+) and tumor-free contralateral (ctrl) kidneys at d7 and d13 post-tumor challenge. “PBS” ...

We then evaluated DC infiltration after renal tumor growth had continued unchecked for more than 3 wks. Advanced tumor outgrowth was accompanied by increased percentages of DC in the tumor-bearing kidneys of DIO mice (Fig. 5B). Again, DC infiltration of contralateral kidneys and spleens remained at low levels in both NW and DIO mice (not shown), indicating that the response was tumor-specific. Therefore, obesity led to increased local DC infiltration in response to advanced renal tumor growth, but did not differentially impact systemic DC that were distal to the tumor site.

Based upon our prior work showing that TIDC from multiple tumor types functioned as suppressor cells (21), we evaluated the inhibitory capacity of renal TIDC from DIO and NW mice. To accomplish this, CD11c+/CD11b+/Gr-1neg DC were sort-purified from the kidneys of mice with advanced renal tumor growth, as evidenced by BLI. Performing DC isolations in this manner allowed us to control for variations in tumor outgrowth rates and to isolate DC when tumor burdens were similar. Following sort-purification, renal DC from tumor-bearing kidneys were put into culture with naive DUC18 T cells (21) and stimulatory tERK peptide-pulsed spDC from young, NW tumor-free mice. We then determined DC suppressive capacity by measuring decreases in T cell proliferation, relative to control wells that contained only T cells and stimulatory spDC. Mean results from 3 independent experiments showed a significantly stronger inhibitory capacity in DC from tumor-bearing kidneys of DIO mice, as compared to counterparts from NW mice (Fig. 5C). The latter showed no ability to suppress naive T cell proliferation. Although the suppressive capacity of DIO TIDC was moderate on a per cell basis, increased frequencies of these cells were present in the tumor-bearing kidneys of DIO mice. This raised the possibility that the net effect might be a noticeable inhibition of tumor-clearance in vivo.

Diminished responsiveness to immunotherapy in DIO mice is accompanied by local increases in suppressive DC and decreased T cell infiltration

The endogenous immune response to Renca tumors is not protective, but we had determined previously that administration of immunotherapy could induce DC- and T cell-dependent Renca eradication in NW mice (18, 30). The therapy we used consisted of Adenovirus-encoded TRAIL (AdTRAIL) (33) plus CpG 1826. TRAIL has been explored as an anti-cancer agent due to its ability to preferentially induce tumor cell death, whereas CpG oligodeoxynucleotides promote DC maturation and enhanced Ag presentation (3437). Successful AdTRAIL+ CpG therapy relies upon DC presentation of Ag derived from apoptotic tumor cells to CD8 T cells, which then become the main effectors of tumor clearance (18, 30). Given the elevated percentages of suppressive DC in tumor-bearing kidneys from DIO mice (Fig. 4), we predicted that DIO mice would have a reduced ability to clear Renca-luciferase tumors following administration of AdTRAIL+ CpG immunotherapy.

DIO and NW mice were challenged intra-renally with Renca-luciferase on d0, followed by either AdTRAIL+ CpG therapy or PBS on d7, at a time when tumor growth was already evident (Fig. 4 and Supplemental Fig. 2A). By d28, both DIO and NW PBS-treated mice had equivalently large renal tumor burdens (Fig. 6A). NW mice that had received AdTRAIL+ CpG on d7 showed a substantial reduction in tumor growth as compared to PBS-treated NW mice (white bars, Fig. 6A). In fact, the total light flux in treated NW mice approximated the background flux seen in tumor-free controls (p > .05), indicating that few tumor cells remained in these kidneys. In contrast, DIO mice that received AdTRAIL+ CpG on d7 showed no decrease in tumor burden relative to PBS-treated DIO mice (black bars, Fig. 6A). To determine whether AdTRAIL+ CpG therapy would show greater efficacy in DIO mice if a different tumor challenge model were used, we injected NW and DIO mice with parental Renca sc on the hind flank. Again, mice were given AdTRAIL+ CpG or sterile PBS peri-tumorally on d7. In this model, AdTRAIL+ CpG was highly effective at reversing tumor growth in NW mice, but produced little benefit in DIO mice (Fig. 6B). An examination of survival in sc-challenged DIO versus NW mice revealed that whereas 80% of NW mice survived long-term after AdTRAIL+ CpG therapy, all treated DIO mice succumbed to their tumors (Supplemental Fig. 3A). Thus, an immunotherapy that was able to reverse uncontrolled tumor outgrowth in NW mice was ineffective in DIO mice.

FIGURE 6
Immunotherapeutic failure in DIO mice is associated with increased percentages of suppressive DC in tumor-bearing kidneys. A, IR tumor growth at d28 post-challenge, as measured by BLI in live mice that received either PBS or AdTRAIL+CpG on d7. Bars indicate ...

We wanted to explore possible mechanisms that might account for this therapeutic failure, and began by assessing expression of the Coxsackie Adenovirus Receptor (CAR) in the kidneys of DIO and NW mice at d7 after IR tumor-challenge. Decreased CAR expression in DIO mice could explain the therapeutic failure we observed, as this would diminish local adenoviral entry into cells and preclude expression of TRAIL. However, DIO mice had increased CAR expression at d7 in tumor-bearing kidneys, negating this possibility (Supplemental Fig. 3B). We then examined the degree of DC infiltration into tumor-bearing kidneys following therapy. We found that tumor-bearing kidneys from DIO mice treated with AdTRAIL+ CpG had increased percentages of DC: approximately 14-fold higher than what was seen in AdTRAIL+ CpG treated NW mice (Fig. 6C). Of note, the percentages of DC present in tumor-bearing kidneys from NW AdTRAIL+ CpG-treated mice were greatly reduced compared to what we had seen in untreated, tumor-bearing NW mice (Fig. 5B). In treated DIO mice, the increased percentage of renal DC was again specific to the tumor site, as increased DC percentages were not evident in non-tumor-bearing contralateral kidneys. The spleens of AdTRAIL+CpG treated DIO mice did trend toward having an increased percentage of DC relative to similarly-treated NW spleens, but this difference was not significant (Fig. 6C).

We next assessed DC function from DIO tumor-bearing kidneys, to determine if administration of immunotherapy had diminished the suppressive capacity of these cells. Experiments similar to those described in Figure 5C were performed, this time using sort-purified renal DC from DIO AdTRAIL+CpG treated mice. Even in the presence of immunotherapy, renal DC from tumor-bearing DIO mice inhibited T cell proliferation (Fig. 6C, upper right panel). Suppressive function was specific to DC from tumor-bearing kidneys, as DC isolated from the spleens of AdTRAIL+CpG treated, tumor-bearing DIO mice showed no inhibition of T cell proliferation (Fig. 6C, lower right panel). Our attempts to evaluate the suppressive function of DC from NW AdTRAIL+ CpG-treated kidneys were unsuccessful, as we were unable to obtain sufficient numbers of these DC for functional evaluation (data not shown). We then stained renal DC from the tumor-bearing kidneys of AdTRAIL+ CpG-treated DIO and NW mice at d21, and again found decreased percentages of CD83+ DC (Fig. 6D). To further investigate the function of DC from tumor-bearing kidneys, we sort-purified DC from NW and DIO mice that had received AdTRAIL+ CpG therapy and evaluated their cytokine production. Renal DC from DIO mice produced less IL-12p70 and TNFα than did their NW counterparts, although their production of IL-1β was equivalent. Both IL-12p70 and TNFα are known to promote protective immunity (29, 38), so a loss in their expression would be predicted to diminish local T cell responses.

To determine whether a decreased local T cell response in DIO mice contributed to immunotherapeutic failure, we evaluated the percentages of CD8+ effector T cells present in the kidneys at d21 after AdTRAIL+ CpG treatment of DIO and NW mice. Tumor-bearing kidneys of treated NW mice showed a significant increase in the percent of CD8+ T cells, relative to tumor-free contralateral kidneys of the same mice (Fig. 7A). In contrast, the T cell response was modest in tumor-bearing kidneys from DIO mice, and was not significantly elevated with respect to contralateral kidneys. Interestingly, the impaired T cell influx observed in DIO mice at d21 was not present at earlier time points; at both d7 and d13 after IR tumor challenge, the percentages of antigen-experienced, CD11ahigh CD8+ T cells (39) in tumor-bearing kidneys from DIO and NW mice were equivalent (Supplemental Figure 3C). We then examined effector function in CD8+ T cells from AdTRAIL+ CpG-treated NW and DIO mice, by staining for intracellular IFNγ. Doing so again revealed a strong T cell response in tumor-bearing kidneys from NW mice (Fig. 7B). Although DIO mice had nearly comparable percentages of CD8 T cells that produced IFNγ (Fig. 7B), the low percentages of T cells present meant that the overall frequency of effector CD8+ T cells present within tumor-bearing kidneys was no greater than that seen in tumor-free contralateral kidneys (Fig. 7C). Finally, to determine whether the cytolytic activity of DIO effector CD8+ T cells were also diminished, we performed an in vivo cytolytic assay using NW and DIO influenza-infected mice, as this model system allowed us to readily evaluate site-specific cytolytic activity in vivo. Decreased cytolytic activity was observed in DIO mice, complementing the results we obtained in our IR Renca tumor model. Thus, a robust, local effector T cell response was lacking in DIO mice.

FIGURE 7
Immunotherapeutic failure in DIO mice is associated with decreased percentages of effector CD8+ T cells in tumor-bearing kidneys. A, Percentages of CD8+ T cells from NW or DIO tumor-bearing kidneys (tum+) and tumor-free contralateral (ctrl) kidneys are ...

Collectively, these results show that DIO renders a normally efficacious immunotherapy largely ineffective, leading to uncontrolled tumor outgrowth. The loss of responsiveness to immunotherapy in DIO mice was accompanied by increased percentages of suppressive DC in tumor-bearing kidneys, and diminished effector T cell responses at the tumor site.

Discussion

Understanding the influence of obesity on immune function, tumor outgrowth, and the efficacy of administered antitumor immunotherapies is of critical importance, given the widespread prevalence of obesity in the U.S. today. In the current study, we used a mouse model of DIO to identify DC functional alterations, both in the absence and presence of orthotopic RCC, a cancer for which obesity is a major risk factor (3). We found that a DC-based immunotherapy was largely ineffective in DIO mice with RCC, although the same therapy was able to control RCC outgrowth in NW mice. This loss of efficacy was accompanied by increased percentages of suppressive DC in tumor-bearing kidneys of DIO mice, and a decreased influx of CD8 T cells into the tumor site.

We identified several obesity-related alterations in DC function in DIO mice. During steady-state conditions, we found that DIO spDC had elevated production of IP-10 (CXCL10) a chemokine that normally regulates local recruitment of macrophages, T cells, NK cells, and DC. As concentrations of this chemokine were also elevated in the serum of DIO mice, this raised the possibility that site-specific T cell trafficking might be impaired in DIO mice. For example, we found decreased CD8+ T cell infiltration of tumor-bearing kidneys after administration of immunotherapy. If elevated systemic IP-10 were causing dysregulated T cell trafficking, we would have expected to see increased percentages of CD8+ T cells in the tumor-free contralateral kidneys of DIO mice, which we did not. Recently, Krinninger et al. reported that adipocytes from mice and humans produce IP-10, which may explain the accumulation of CD8+ T cells seen in obese adipose tissue in other models (40). In addition, increased systemic leptin concentrations have been associated with increased numbers, percentages, and suppressive activities of CD4+ regulatory T cells during obesity (41). Therefore, it is possible that decreased T cell infiltration into the tumor site was due to a combination of Treg-mediated inhibition of effector T cell expansion and IP-10-mediated abnormalities in T cell trafficking. We did not examine adipose tissue in our DIO mice to determine if CD8+ T cells were also accumulating there during tumor outgrowth, rather than trafficking to the tumor site.

We also found that spDC from DIO mice had a reduced ability to stimulate naive T cell proliferation, a fact that also could have contributed to the decreased T cell response we observed in tumor-bearing DIO mice receiving immunotherapy. One explanation for the observed changes in DIO spDC function is elevated systemic lipid availability, as intracellular lipid accumulation has recently been shown to impair DC function in mice with tumors; in that study, normalization of DC lipid content via pharmacological inhibition improved DC function (42). Another possibility is that DC function is impaired due to the unique cytokine milieu present systemically in DIO mice. Several of the factors that were elevated in the serum of DIO mice are known to impact the function of DC and other leukocytes. For example, leptin is a protein that functions both as a hormone and a cytokine, and is produced at elevated levels by visceral adipocytes in the obese. Leptin is structurally similar to IL-6, and has a wide range of effects on the immune system: it enhances phagocytosis in macrophages, it supports the differentiation and cytolytic activity of NK cells, it promotes Th differentiation toward a Th1 state, and it has been shown to enhance the maturation of bone-marrow derived DC in culture (43, 44). From these findings, one might predict that DIO mice would have DC with enhanced stimulatory capacities. However, leptin is just one cytokine that was elevated in DIO mice; other factors acting singly or in combination may counteract its effects. One example is eotaxin (CCL11), which was increased in the serum of DIO mice, and has been shown to impede DC differentiation through activation of the suppressor of cytokine signaling (SOCS) (45).

Our study illustrated that the combination of obesity and tumor outgrowth leads to a markedly impaired DC response to RCC in this orthotopic murine model. We observed increased infiltration of DC into tumor-bearing kidneys of DIO mice in the presence and absence of immunotherapy. Rather than inducing T cell proliferation, the DC that infiltrated tumor-bearing kidneys in DIO mice inhibited T cell expansion (Fig. 5C and and6C).6C). This was in contrast to the DC from tumor-bearing kidneys in NW mice, which did not show any ability to suppress T cell proliferation. In DIO mice, suppression of T cell expansion occurred even after administration of a combinatorial therapy that contained CpG1826. CpG1826 is an unmethylated oligonucleotide known to induce DC maturation and Ag presentation in NW mice, and it is being investigated as an anti-cancer therapeutic for several tumor types (34). Despite this, treated DIO mice showed decreased percentages of CD83+ mature DC in tumor-bearing kidneys (Fig. 6D), and also produced less of the immunoprotective cytokines IL-12 and TNFα (Fig. 6D). These results highlight the necessity of examining immunotherapeutic efficacy in both NW and obese mice, as the altered physiology of the latter may negatively impact results.

Using two murine breast cancer models and a fibrosarcoma model, we previously found that TIDC from young, NW mice were able to inhibit T cell expansion ex vivo (21). Although the degree of inhibition varied according to the tumor model being examined, all TIDC showed some ability to suppress T cell expansion. Because of this, we were initially surprised to find that DC from RCC-bearing kidneys in NW mice did not inhibit T cell proliferation. Several factors may account for this finding. First, there were low percentages of DC present in tumor-bearing kidneys from NW mice. Second, it was impossible for us to determine whether those low numbers of renal DC were actually infiltrating tumor masses within kidneys, or were located in normal tissue adjacent to malignant areas. The use of BLI allowed us to monitor tumor growth in live mice, so we were able to objectively determine that all mice used for experiments had progressively growing tumors by d7. However, even after several weeks of tumor growth, when most DC experiments were performed, it was frequently impossible to identify distinct tumor masses upon gross examination of excised kidneys. To validate our BLI results, several tumor-bearing kidneys were sectioned and stained for histological evaluation, and all were found to contain renal tumors (data not shown). Consequently, we could not determine the relative ratios of true “TIDC” versus the broader population of renal DC. It is possible that many of the renal DC from tumor-bearing NW mice had resided in healthy kidney tissue, rather than in the developing tumor mass.

In our study, BLI and flow cytometric analyses revealed that early RCC outgrowth was more rapid in DIO mice than in NW counterparts (Fig. 4A and C), but these differences were not sustained (Fig. 5A). While accelerated tumor outgrowth has been reported in other models of murine obesity, this trend is not universally observed (4649). The variable responses of tumor growth to ongoing obesity likely stem from the unique responses of each tumor cell type to the cytokine/ chemokine environment present in the host. Leptin is known to promote angiogenesis through increased expression of VEGF, to promote tumor cell proliferation in vitro, and to increase tumor cell resistance to apoptosis (50). These actions could have promoted the increased early tumor growth we observed, and could also have contributed to the decreased efficacy of AdTRAIL+CpG therapy in DIO mice. It is also likely that elevated concentrations of inflammatory mediators influenced the rapid, early tumor outgrowth in DIO mice. Previous studies in a mouse that lacks white adipose tissue, and therefore lacks leptin, but still develops insulin resistance and chronic inflammation, implicated inflammation as a key factor in accelerated tumor outgrowth (51). In agreement with this idea, numerous studies in NW mice have demonstrated that chronic inflammation supports tumor outgrowth and suppresses antitumor immunity (5256). As prostaglandin E2 (PGE2) is a critical mediator of inflammation and is elevated during obesity in response to high levels of cytokines such as IL-1β and IL-18 (57), it is possible that blocking this pathway might have benefits in terms of reducing tumor burdens and/or normalizing anti-tumor immunity in obese individuals, an idea that could be addressed in future experiments.

We show here that tumor-free DIO BALB/c mice have increased serum concentrations of multiple pro-inflammatory cytokines (Table I). Several of these have been previously shown to augment tumor outgrowth. For example, IL-13 and IFNγ were shown previously to support breast cancer growth in mice (58). IL-1α has been linked to breast cancer metastasis (59). LIF has been shown to promote accelerated growth of kidney, breast, and prostate cancer cells (6062). The net effect of these and other factors on tumor growth is not known. Interestingly, the pattern of cytokine/ chemokine alterations we observed in BALB/c DIO versus NW mice were distinct from those reported previously for DIO C57Bl/6 mice (11). For example, we found higher serum concentrations of IL-1α, IL-2, IL-12p40, IL-13, IL-17, and eotaxin in DIO mice, whereas these same proteins were expressed at equal or lower levels in the serum of DIO C57Bl/6 mice, relative to NW C57Bl/6 mice (11). Therefore, underlying strain differences may affect not only serum cytokine/ chemokine profiles, but might also influence tumor outgrowth rates.

DC responses to tumor outgrowth are critical factors that impact the success or failure of many immunotherapeutic strategies being employed or developed today. New treatment options are illustrating the potential for DC-based immunotherapies to prolong the lives of cancer patients. One such example is Provenge™, a biologic therapy that relies upon autologous DC presentation of tumor-derived Ag to stimulate protective antitumor immunity in prostate cancer patients (63). Alternate approaches, such as GVAX, which relies upon GM-CSF administration to increase tumor Ag delivery to endogenous DC, are also showing promise in clinical trials (64). Many other therapies, such as recombinant human TRAIL or agonistic TRAIL receptor antibodies, work by increasing tumor cell death, and these also rely upon endogenous DC to process and present tumor cell Ag to the immune system (36, 65, 66). The confounding effects of obesity on these and other DC-based cancer immunotherapies are not known. We found that baseline DC stimulatory capacity was diminished in DIO mice, and that DC from DIO tumor-bearing kidneys suppressed T cell expansion ex vivo. Ultimately, administration of a DC-dependent anti-cancer therapy was found to be ineffective in DIO mice with RCC. Our results suggest that both pre-clinical studies in mice and clinical trials in cancer patients may benefit from examining the efficacy of DC-based immunotherapies in the presence of obesity and its associated inflammation.

Supplementary Material

Acknowledgments

We thank the excellent staff at the University of Iowa Office of Animal Resources, the Flow Cytometry Facility, and the Central Microscopy Core Facility for their expert technical assistance.

This work was supported by an American Cancer Society grant to the University of Iowa Holden Comprehensive Cancer Center (LAN), National Institutes of Health Grant CA109446 (TSG), and Department of Defense Grant W81XWH-11-1-0271 (TSG)

Abbreviations used in this article

RCC
renal cell carcinoma
DC
dendritic cell
spDC
splenic dendritic cell
DIO
diet-induced obesity
HFF
high fat feed
NW
normal weight
IR
intra-renal

References

1. Calle EE, Kaaks R. Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms. Nat Rev Cancer. 2004;4:579–591. [PubMed]
2. Klinghoffer Z, Yang B, Kapoor A, Pinthus JH. Obesity and renal cell carcinoma: epidemiology, underlying mechanisms and management considerations. Expert Rev Anticancer Ther. 2009;9:975–987. [PubMed]
3. Chow WH, Dong LM, Devesa SS. Epidemiology and risk factors for kidney cancer. Nat Rev Urol. 2010;7:245–257. [PMC free article] [PubMed]
4. Maya-Monteiro CM, Bozza PT. Leptin and mTOR: partners in metabolism and inflammation. Cell Cycle. 2008;7:1713–1717. [PubMed]
5. Fontana L, Eagon JC, Trujillo ME, Scherer PE, Klein S. Visceral fat adipokine secretion is associated with systemic inflammation in obese humans. Diabetes. 2007;56:1010–1013. [PubMed]
6. Hotamisligil GS. Inflammation and metabolic disorders. Nature. 2006;444:860–867. [PubMed]
7. Wisse BE. The inflammatory syndrome: the role of adipose tissue cytokines in metabolic disorders linked to obesity. J Am Soc Nephrol. 2004;15:2792–2800. [PubMed]
8. Gregor MF, Hotamisligil GS. Inflammatory Mechanisms in Obesity. Annu Rev Immunol. 2010 [PubMed]
9. Xu H, Barnes GT, Yang Q, Tan G, Yang D, Chou CJ, Sole J, Nichols A, Ross JS, Tartaglia LA, Chen H. Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J Clin Invest. 2003;112:1821–1830. [PMC free article] [PubMed]
10. Lee IS, Shin G, Choue R. Shifts in diet from high fat to high carbohydrate improved levels of adipokines and pro-inflammatory cytokines in mice fed a high-fat diet. Endocr J. 2009;57:39–50. [PubMed]
11. Fenton JI, Nunez NP, Yakar S, Perkins SN, Hord NG, Hursting SD. Diet-induced adiposity alters the serum profile of inflammation in C57BL/6N mice as measured by antibody array. Diabetes Obes Metab. 2009;11:343–354. [PubMed]
12. Macia L, Delacre M, Abboud G, Ouk TS, Delanoye A, Verwaerde C, Saule P, Wolowczuk I. Impairment of dendritic cell functionality and steady-state number in obese mice. J Immunol. 2006;177:5997–6006. [PubMed]
13. Smith AG, Sheridan PA, Tseng RJ, Sheridan JF, Beck MA. Selective impairment in dendritic cell function and altered antigen-specific CD8+ T-cell responses in diet-induced obese mice infected with influenza virus. Immunology. 2009;126:268–279. [PubMed]
14. Verwaerde C, Delanoye A, Macia L, Tailleux A, Wolowczuk I. Influence of high-fat feeding on both naive and antigen-experienced T-cell immune response in DO10.11 mice. Scand J Immunol. 2006;64:457–466. [PubMed]
15. Kim CS, Lee SC, Kim YM, Kim BS, Choi HS, Kawada T, Kwon BS, Yu R. Visceral fat accumulation induced by a high-fat diet causes the atrophy of mesenteric lymph nodes in obese mice. Obesity (Silver Spring) 2008;16:1261–1269. [PubMed]
16. Lumeng CN, DelProposto JB, Westcott DJ, Saltiel AR. Phenotypic switching of adipose tissue macrophages with obesity is generated by spatiotemporal differences in macrophage subtypes. Diabetes. 2008;57:3239–3246. [PMC free article] [PubMed]
17. Karlsson EA, Sheridan PA, Beck MA. Diet-induced obesity impairs the T cell memory response to influenza virus infection. J Immunol. 2010;184:3127–3133. [PubMed]
18. VanOosten RL, Griffith TS. Activation of tumor-specific CD8+ T Cells after intratumoral Ad5-TRAIL/CpG oligodeoxynucleotide combination therapy. Cancer Res. 2007;67:11980–11990. [PubMed]
19. Svensson RU, Barnes JM, Rokhlin OW, Cohen MB, Henry MD. Chemotherapeutic agents up-regulate the cytomegalovirus promoter: implications for bioluminescence imaging of tumor response to therapy. Cancer Res. 2007;67:10445–10454. [PubMed]
20. Drake JM, Gabriel CL, Henry MD. Assessing tumor growth and distribution in a model of prostate cancer metastasis using bioluminescence imaging. Clin Exp Metastasis. 2005;22:674–684. [PubMed]
21. Norian LA, Rodriguez PC, O'Mara LA, Zabaleta J, Ochoa AC, Cella M, Allen PM. Tumor-infiltrating regulatory dendritic cells inhibit CD8+ T cell function via L-arginine metabolism. Cancer Res. 2009;69:3086–3094. [PMC free article] [PubMed]
22. Hanson HL, Donermeyer DL, Ikeda H, White JM, Shankaran V, Old LJ, Shiku H, Schreiber RD, Allen PM. Eradication of established tumors by CD8+ T cell adoptive immunotherapy. Immunity. 2000;13:265–276. [PubMed]
23. Norian LA, Allen PM. Rapid maturation of effector T cells in tumors, but not lymphoid organs, during tumor regression. PLoS One. 2007;2:e821. [PMC free article] [PubMed]
24. Lumeng CN, Bodzin JL, Saltiel AR. Obesity induces a phenotypic switch in adipose tissue macrophage polarization. J Clin Invest. 2007;117:175–184. [PMC free article] [PubMed]
25. Vosshenrich CA, Lesjean-Pottier S, Hasan M, Richard-Le Goff O, Corcuff E, Mandelboim O, Di Santo JP. CD11cloB220+ interferon-producing killer dendritic cells are activated natural killer cells. J Exp Med. 2007;204:2569–2578. [PMC free article] [PubMed]
26. Blasius AL, Barchet W, Cella M, Colonna M. Development and function of murine B220+CD11c+NK1.1+ cells identify them as a subset of NK cells. J Exp Med. 2007;204:2561–2568. [PMC free article] [PubMed]
27. Ballesteros-Tato A, Leon B, Lund FE, Randall TD. Temporal changes in dendritic cell subsets, cross-priming and costimulation via CD70 control CD8(+) T cell responses to influenza. Nat Immunol. 2010;11:216–224. [PMC free article] [PubMed]
28. Norian LA, Allen PM. No intrinsic deficiencies in CD8+ T cell-mediated antitumor immunity with aging. J Immunol. 2004;173:835–844. [PubMed]
29. Mescher MF, Curtsinger JM, Agarwal P, Casey KA, Gerner M, Hammerbeck CD, Popescu F, Xiao Z. Signals required for programming effector and memory development by CD8+ T cells. Immunol Rev. 2006;211:81–92. [PubMed]
30. Norian LA, Kresowik TP, Rosevear HM, James BR, Rosean TR, Lightfoot AJ, Kucaba TA, Schwarz C, Weydert CJ, Henry MD, Griffith TS. Eradication of metastatic renal cell carcinoma after adenovirus-encoded TNF-related apoptosis-inducing ligand (TRAIL)/CpG immunotherapy. PLoS One. 2012;7:e31085. [PMC free article] [PubMed]
31. Abdool K, Cretney E, Brooks AD, Kelly JM, Swann J, Shanker A, Bere EW, Jr, Yokoyama WM, Ortaldo JR, Smyth MJ, Sayers TJ. NK cells use NKG2D to recognize a mouse renal cancer (Renca), yet require intercellular adhesion molecule-1 expression on the tumor cells for optimal perforin-dependent effector function. J Immunol. 2006;177:2575–2583. [PubMed]
32. Pufnock JS, Cigal M, Rolczynski LS, Andersen-Nissen E, Wolfl M, McElrath MJ, Greenberg PD. Priming CD8+ T cells with dendritic cells matured using TLR4 and TLR7/8 ligands together enhances generation of CD8+ T cells retaining CD28. Blood. 2011;117:6542–6551. [PubMed]
33. Griffith TS, Anderson RD, Davidson BL, Williams RD, Ratliff TL. Adenoviral-mediated transfer of the TNF-related apoptosis-inducing ligand/Apo-2 ligand gene induces tumor cell apoptosis. J Immunol. 2000;165:2886–2894. [PubMed]
34. Krieg AM. Development of TLR9 agonists for cancer therapy. J Clin Invest. 2007;117:1184–1194. [PMC free article] [PubMed]
35. Ashkenazi A, Pai RC, Fong S, Leung S, Lawrence DA, Marsters SA, Blackie C, Chang L, McMurtrey AE, Hebert A, DeForge L, Koumenis IL, Lewis D, Harris L, Bussiere J, Koeppen H, Shahrokh Z, Schwall RH. Safety and antitumor activity of recombinant soluble Apo2 ligand. J Clin Invest. 1999;104:155–162. [PMC free article] [PubMed]
36. Holoch PA, Griffith TS. TNF-related apoptosis-inducing ligand (TRAIL): a new path to anti-cancer therapies. Eur J Pharmacol. 2009;625:63–72. [PMC free article] [PubMed]
37. Wiley SR, Schooley K, Smolak PJ, Din WS, Huang CP, Nicholl JK, Sutherland GR, Smith TD, Rauch C, Smith CA, et al. Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity. 1995;3:673–682. [PubMed]
38. Chen Z, Moyana T, Saxena A, Warrington R, Jia Z, Xiang J. Efficient antitumor immunity derived from maturation of dendritic cells that had phagocytosed apoptotic/necrotic tumor cells. Int J Cancer. 2001;93:539–548. [PubMed]
39. Rai D, Pham NL, Harty JT, Badovinac VP. Tracking the total CD8 T cell response to infection reveals substantial discordance in magnitude and kinetics between inbred and outbred hosts. J Immunol. 2009;183:7672–7681. [PMC free article] [PubMed]
40. Krinninger P, Brunner C, Ruiz PA, Schneider E, Marx N, Foryst-Ludwig A, Kintscher U, Haller D, Laumen H, Hauner H. Role of the adipocyte-specific NF-kappaB activity in the regulation of IP-10 and T cell migration. Am J Physiol Endocrinol Metab. 2011;300:E304–E311. [PubMed]
41. Matarese G, Procaccini C, De Rosa V, Horvath TL, La Cava A. Regulatory T cells in obesity: the leptin connection. Trends Mol Med. 2010;16:247–256. [PubMed]
42. Herber DL, Cao W, Nefedova Y, Novitskiy SV, Nagaraj S, Tyurin VA, Corzo A, Cho HI, Celis E, Lennox B, Knight SC, Padhya T, McCaffrey TV, McCaffrey JC, Antonia S, Fishman M, Ferris RL, Kagan VE, Gabrilovich DI. Lipid accumulation and dendritic cell dysfunction in cancer. Nat Med. 2010;16:880–886. [PMC free article] [PubMed]
43. Lago R, Gomez R, Lago F, Gomez-Reino J, Gualillo O. Leptin beyond body weight regulation--current concepts concerning its role in immune function and inflammation. Cell Immunol. 2008;252:139–145. [PubMed]
44. Lam QL, Liu S, Cao X, Lu L. Involvement of leptin signaling in the survival and maturation of bone marrow-derived dendritic cells. Eur J Immunol. 2006;36:3118–3130. [PubMed]
45. Stevenson NJ, Addley MR, Ryan EJ, Boyd CR, Carroll HP, Paunovic V, Bursill CA, Miller HC, Channon KM, McClurg AE, Armstrong MA, Coulter WA, Greaves DR, Johnston JA. CCL11 blocks IL-4 and GM-CSF signaling in hematopoietic cells and hinders dendritic cell differentiation via suppressor of cytokine signaling expression. J Leukoc Biol. 2009;85:289–297. [PubMed]
46. Hakkak R, Holley AW, Macleod SL, Simpson PM, Fuchs GJ, Jo CH, Kieber-Emmons T, Korourian S. Obesity promotes 7,12-dimethylbenz(a)anthracene-induced mammary tumor development in female zucker rats. Breast Cancer Res. 2005;7:R627–R633. [PMC free article] [PubMed]
47. Le TT, Huff TB, Cheng JX. Coherent anti-Stokes Raman scattering imaging of lipids in cancer metastasis. BMC Cancer. 2009;9:42. [PMC free article] [PubMed]
48. Cleary MP, Grande JP, Juneja SC, Maihle NJ. Diet-induced obesity and mammary tumor development in MMTV-neu female mice. Nutr Cancer. 2004;50:174–180. [PubMed]
49. Rose DP, Connolly JM. Regulation of tumor angiogenesis by dietary fatty acids and eicosanoids. Nutr Cancer. 2000;37:119–127. [PubMed]
50. Lang K, Ratke J. Leptin and Adiponectin: new players in the field of tumor cell and leukocyte migration. Cell Commun Signal. 2009;7:27. [PMC free article] [PubMed]
51. Nunez NP, Oh WJ, Rozenberg J, Perella C, Anver M, Barrett JC, Perkins SN, Berrigan D, Moitra J, Varticovski L, Hursting SD, Vinson C. Accelerated tumor formation in a fatless mouse with type 2 diabetes and inflammation. Cancer Res. 2006;66:5469–5476. [PubMed]
52. Vakkila J, Lotze MT. Inflammation and necrosis promote tumour growth. Nat Rev Immunol. 2004;4:641–648. [PubMed]
53. Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature. 2008;454:436–444. [PubMed]
54. Krelin Y, Voronov E, Dotan S, Elkabets M, Reich E, Fogel M, Huszar M, Iwakura Y, Segal S, Dinarello CA, Apte RN. Interleukin-1beta-driven inflammation promotes the development and invasiveness of chemical carcinogen-induced tumors. Cancer Res. 2007;67:1062–1071. [PubMed]
55. Coussens LM, Werb Z. Inflammation and cancer. Nature. 2002;420:860–867. [PMC free article] [PubMed]
56. Kim S, Takahashi H, Lin WW, Descargues P, Grivennikov S, Kim Y, Luo JL, Karin M. Carcinoma-produced factors activate myeloid cells through TLR2 to stimulate metastasis. Nature. 2009;457:102–106. [PMC free article] [PubMed]
57. Osborn O, Gram H, Zorrilla EP, Conti B, Bartfai T. Insights into the roles of the inflammatory mediators IL-1, IL-18 and PGE2 in obesity and insulin resistance. Swiss Med Wkly. 2008;138:665–673. [PubMed]
58. Aspord C, Pedroza-Gonzalez A, Gallegos M, Tindle S, Burton EC, Su D, Marches F, Banchereau J, Palucka AK. Breast cancer instructs dendritic cells to prime interleukin 13-secreting CD4+ T cells that facilitate tumor development. J Exp Med. 2007;204:1037–1047. [PMC free article] [PubMed]
59. Nozaki S, Sledge GW, Jr, Nakshatri H. Cancer cell-derived interleukin 1alpha contributes to autocrine and paracrine induction of pro-metastatic genes in breast cancer. Biochem Biophys Res Commun. 2000;275:60–62. [PubMed]
60. Kellokumpu-Lehtinen P, Talpaz M, Harris D, Van Q, Kurzrock R, Estrov Z. Leukemia-inhibitory factor stimulates breast, kidney and prostate cancer cell proliferation by paracrine and autocrine pathways. Int J Cancer. 1996;66:515–519. [PubMed]
61. Piccinni MP, Scaletti C, Vultaggio A, Maggi E, Romagnani S. Defective production of LIF, M-CSF and Th2-type cytokines by T cells at fetomaternal interface is associated with pregnancy loss. J Reprod Immunol. 2001;52:35–43. [PubMed]
62. Gao W, Thompson L, Zhou Q, Putheti P, Fahmy TM, Strom TB, Metcalfe SM. Treg versus Th17 lymphocyte lineages are cross-regulated by LIF versus IL-6. Cell Cycle. 2009;8:1444–1450. [PMC free article] [PubMed]
63. Carballido E, Fishman M. Sipuleucel-T: Prototype for Development of Anti-tumor Vaccines. Curr Oncol Rep. 2011 [PubMed]
64. Le DT, Pardoll DM, Jaffee EM. Cellular vaccine approaches. Cancer J. 2010;16:304–310. [PMC free article] [PubMed]
65. Younes A, Vose JM, Zelenetz AD, Smith MR, Burris HA, Ansell SM, Klein J, Halpern W, Miceli R, Kumm E, Fox NL, Czuczman MS. A Phase 1b/2 trial of mapatumumab in patients with relapsed/refractory non-Hodgkin's lymphoma. Br J Cancer. 2010;103:1783–1787. [PMC free article] [PubMed]
66. Wang S. TRAIL: a sword for killing tumors. Curr Med Chem. 2010;17:3309–3317. [PubMed]